Who are K-924 LD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ropinirole CR-RLS, IM aripiprazole once monthly, Ropinirole (Requip), aripiprazole long acting injectable formulation, Raclopride C11, [11C]raclopride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/k-924-ld.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

K-924 LD — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

K-924 LD (K-924 LD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine D2/D3 receptor agonist. Area: Neurology.

phase 3 Dopamine D2/D3 receptor agonist Dopamine D2 receptor, Dopamine D3 receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

K-924 LD (K-924 LD) — Kowa Company, Ltd.. K-924 LD is a long-acting dopamine D2/D3 receptor agonist designed to provide sustained dopaminergic activity for extended treatment intervals.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
K-924 LD TARGET	K-924 LD	Kowa Company, Ltd.	phase 3	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
ropinirole CR-RLS	ropinirole CR-RLS	GlaxoSmithKline	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
IM aripiprazole once monthly	IM aripiprazole once monthly	University of Utah	marketed	Atypical antipsychotic	Dopamine D2 receptor, Dopamine D3 receptor
Ropinirole (Requip)	Ropinirole (Requip)	St. Luke's-Roosevelt Hospital Center	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
aripiprazole long acting injectable formulation	aripiprazole long acting injectable formulation	Vanguard Research Group	marketed	Atypical antipsychotic (dopamine partial agonist)	Dopamine D2 receptor, Dopamine D3 receptor
Raclopride C11	Raclopride C11	University of North Carolina, Chapel Hill	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
[11C]raclopride	[11C]raclopride	New York State Psychiatric Institute	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine D2/D3 receptor agonist class)

GlaxoSmithKline · 1 drug in this class
Kowa Company, Ltd. · 1 drug in this class
Pharma Two B Ltd. · 1 drug in this class
St. Luke's-Roosevelt Hospital Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). K-924 LD — Competitive Intelligence Brief. https://druglandscape.com/ci/k-924-ld. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing